USP35 and breast cancer: 18/22 (81.8%) of the clinical breast cancer specimens and 9/11(81.8%) of the lung cancer specimens had lower USP35 mRNA levels than adjacent normal tissues (Figure 2A; Supplementary Figure S2A).